» Authors » L James Lee

L James Lee

Explore the profile of L James Lee including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 156
Citations 3657
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Nguyen K, Rima X, Nguyen L, Wang X, Kwak K, Yoon M, et al.
Adv Healthc Mater . 2024 May; 14(3):e2400622. PMID: 38820600
Virion-mediated outbreaks are imminent and despite rapid responses, continue to cause adverse symptoms and death. Therefore, tunable, sensitive, high-throughput assays are needed to help diagnose future virion-mediated outbreaks. Herein, it...
2.
Pan J, Wang X, Chiang C, Ma Y, Cheng J, Bertani P, et al.
Lab Chip . 2024 Jan; 24(4):819-831. PMID: 38235543
Localized micro/nano-electroporation (MEP/NEP) shows tremendous potential in cell transfection with high cell viability, precise dose control, and good transfection efficacy. In MEP/NEP, micro or nanochannels are used to tailor the...
3.
Li H, Chiang C, Kwak K, Wang X, Doddi S, Ramanathan L, et al.
Adv Sci (Weinh) . 2024 Jan; 11(11):e2306373. PMID: 38204202
Detecting pancreatic duct adenocarcinoma (PDAC) in its early stages and predicting late-stage patient prognosis undergoing chemotherapy is challenging. This work shows that the activation of specific oncogenes leads to elevated...
4.
Zhang J, Rima X, Wang X, Nguyen L, Huntoon K, Ma Y, et al.
J Extracell Vesicles . 2023 Nov; 12(11):e12369. PMID: 37908159
The molecular heterogeneity of extracellular vesicles (EVs) and the co-isolation of physically similar particles, such as lipoproteins (LPs), confounds and limits the sensitivity of EV bulk biomarker characterization. Herein, we...
5.
Chiang C, Ma Y, Hou Y, Pan J, Chen S, Chien M, et al.
Nat Commun . 2023 Oct; 14(1):6692. PMID: 37872156
Pancreatic ductal adenocarcinoma (PDAC) tumours carry multiple gene mutations and respond poorly to treatments. There is currently an unmet need for drug carriers that can deliver multiple gene cargoes to...
6.
Saviana M, Romano G, McElroy J, Nigita G, Distefano R, Toft R, et al.
Front Oncol . 2023 Oct; 13:1255527. PMID: 37869089
Introduction: Small cell lung cancer (SCLC) is characterized by poor prognosis and challenging diagnosis. Screening in high-risk smokers results in a reduction in lung cancer mortality, however, screening efforts are...
7.
Dong S, Liu X, Bi Y, Wang Y, Antony A, Lee D, et al.
Nat Commun . 2023 Oct; 14(1):6610. PMID: 37857647
The recent success of mRNA therapeutics against pathogenic infections has increased interest in their use for other human diseases including cancer. However, the precise delivery of the genetic cargo to...
8.
Nguyen L, Zhang J, Rima X, Wang X, Kwak K, Okimoto T, et al.
J Extracell Vesicles . 2022 Sep; 11(9):e12258. PMID: 36093740
Conventional PD-L1 immunohistochemical tissue biopsies only predict 20%-40% of non-small cell lung cancer (NSCLC) patients that will respond positively to anti-PD-1/PD-L1 immunotherapy. Herein, we present an immunogold biochip to quantify...
9.
Mateescu B, Jones J, Alexander R, Alsop E, An J, Asghari M, et al.
iScience . 2022 Aug; 25(8):104653. PMID: 35958027
The extracellular RNA communication consortium (ERCC) is an NIH-funded program aiming to promote the development of new technologies, resources, and knowledge about exRNAs and their carriers. After Phase 1 (2013-2018),...
10.
Goswami S, Chiang C, Zapolnik K, Nunes J, Ventura A, Mo X, et al.
Leuk Res . 2022 May; 118:106872. PMID: 35640397
No abstract available.